Leukemia Research Studies

< Back to Pediatric Cancer Research Studies Page

AML Relapse / Refractory

AAML1421: A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)

  • Conditions: Leukemia AML Relapse, Adult - Leukemia AML Relapse

PURPOSE: This phase I/II trial studies the side effects and best dose of liposomal cytarabine-daunorubicin CPX-351 (CPX-351) when given with fludarabine phosphate, cytarabine, and filgrastim and to see how well they work in treating younger patients with acute myeloid leukemia that has come back aft ...More

AAML1522: A Phase II, Multicenter, single-arm, open label study to evaluate the activity, safety, and pharmacokinetics of Lenalidomide (REVLIMID®) in Pediatric subjections from 1 to 18 Years of age with Relapsed or Refractory Acute Myeloid Leukemia

  • Conditions: Leukemia AML Relapse

PURPOSE: To determine the activity of lenalidomide in the treatment of pediatric subjects with relapsed/refractory AML (with second or greater relapse or refractory to at least 2 prior induction attempts) measured by morphological complete response defined as either a CR or CRi within the fir ...More

CPX-MA-1201: A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults with Recurrent or Refractory Hematologic Malignancies.

  • Conditions: Lymphoma Hodgkin Relapse, Lymphoma Non Hodgkin Relapse, Leukemia ALL Relapse, Leukemia AML Relapse, Adult - Leukemia AML Relapse, Adult - Leukemia ALL Relapse, Adult - Lymphoma Non Hodgkin Relapse, Adult - Lymphoma Hodgkin Relapse

  PURPOSE: The purpose of this study is to test the safety of a study drug called CPX-351. This drug has been tested in adults but not yet in children and adolescents. This study tests different doses of the drug to see which dose is safer in children and adolescents. Patients who have blood ca ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.